Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Aynaz Rostami
Feb 11, 2021 9:57AM ET
what's the reason of fall of Genfit?
0
0
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🙌 It's Here: the Only Stock Screener You'll Ever Need Get Started
Genfit (GNFT)
Paris
| Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| GNFT | Paris | EUR | Real-time | |
| GNFTp | BATS Europe | EUR | Delayed | |
| GNFT | NASDAQ | USD | Real-time |
Add to/Remove from Watchlist
Add to Watchlist
3.85
+0.04
+0.92%
- Volume: 58,988
- Bid/Ask: 0.00 / 0.00
- Day's Range: 3.80 - 3.88
Genfit
3.85
+0.04
+0.92%
- General
- Chart
- News & Analysis
- Financials
- Technical
- Forum
- Financial Summary
- Income Statement
- Balance Sheet
- Cash Flow
- Ratios
- Dividends
- Earnings
EPA:GNFT Financials
A brief overview of the EPA:GNFT financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Genfit over time.
Genfit S.A. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was EUR 20.2 million compared to EUR 80.07 million a year ago. Revenue was EUR 26.57 million compared to EUR 85.58 million a year ago. Net loss was EUR 23.72 million compared to net income of EUR 67.26 million a year ago. Basic loss per share from continuing operations was EUR 0.48 compared to basic earnings per share from continuing operations of EUR 1.51 a year ago. Diluted loss per share from continuing operations was EUR 0.48 compared to diluted earnings per share from continuing operations of EUR 1.23 a year ago.
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter
GNFT Income Statement
Gross margin TTM 100%
Operating margin TTM -105.3%
Net Profit margin TTM -90.37%
Return on Investment TTM -13.09%
Total Revenue Net Income
| Period Ending: | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|
| Total Revenue | 7.05 | 7.05 | 6.07 | 6.07 |
| Gross Profit | 7.05 | 7.05 | 6.07 | 6.07 |
| Operating Income | -6.56 | -6.56 | -7.26 | -7.26 |
| Net Income | -6.66 | -6.66 | -5.2 | -5.2 |
GNFT Balance Sheet
Quick Ratio MRQ 3.65
Current Ratio MRQ 4.02
LT Debt to Equity MRQ 68.41%
Total Debt to Equity MRQ 79.63%
Total Assets Total Liabilities
| Period Ending: | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|
| Total Assets | 215.54 | 215.54 | 237.05 | 237.05 |
| Total Liabilities | 121.01 | 121.01 | 127.88 | 127.88 |
| Total Equity | 94.53 | 94.53 | 109.17 | 109.17 |
GNFT Cash Flow Statement
Cash Flow/Share TTM -1.46
Revenue/Share TTM 0.53
Operating Cash Flow -31.93%
Cash Net Change in Cash
| Period Ending: | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|
| Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
| Cash From Operating Activities | -12.57 | -12.57 | -23.75 | -23.75 |
| Cash From Investing Activities | -23.03 | -23.03 | -0.1 | -0.1 |
| Cash From Financing Activities | -0.922 | -0.922 | -0.972 | -0.972 |
| Net Change in Cash | -36.56 | -36.56 | -24.82 | -24.82 |
* In Millions of (except for per share items)
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Write your thoughts about Genfit
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
ziqing liew
Feb 11, 2021 9:57AM ET
i also want to know
1
0
Aynaz Rostami
Feb 11, 2021 9:57AM ET
dont worry it Will raise soon
0
1
Thao Bui
Jun 26, 2020 4:57AM ET
it cheap to buy
0
0
CAC Invest
Jun 09, 2020 5:39AM ET
Trials for NASH will continue after dataset correction
0
2
Koprnk
Jun 04, 2020 6:57AM ET
they failed the drug test and NASH drug was the only viable drug that they were developing , so practically they lost almost all value with that failure...
1
1
CAC Invest
Jun 04, 2020 6:57AM ET
not all value but a drug development. they have so many programs to continue
1
0
Danny Danny
May 21, 2020 1:03PM ET
damn what was wrong w this beast? from 2x all the way down to 5 w low volume?
1
0
Rajaie Issaid
May 20, 2020 4:15PM ET
Whats the status , will it still go down ?
0
0
Malek Brahmi
May 20, 2020 4:15PM ET
Yes
0
0
stats con chris
May 19, 2020 2:27PM ET
this baby Is the brother of contravirpharma (HEPA) .. same diseases.
0
0
MfB Iod
May 19, 2020 2:27PM ET
what do you mean?
0
0
Nedal Aysheh
May 12, 2020 5:53PM ET
WHAT IS THE BEST STOCK TO BUY TODAY ??/ ANT RECOMMENDATION
1
0
MfB Iod
Mar 27, 2019 12:56PM ET
does anyone have an explaination for the sudden fall same day of the Nasdaq trading?
1
0
Mathieu Gandrille
Mar 27, 2019 12:56PM ET
Mathieu Gandrille
Mar 27, 2019 12:56PM ET
MfB Iod
Mar 27, 2019 12:56PM ET
Mathieu Gandrille ah you mean to buy because it would be oversold
0
0
Mathieu Gandrille
Mar 27, 2019 12:56PM ET
Olivier Bclr
Mar 27, 2019 12:56PM ET
Mathieu Gandrille are you a KOL?
0
0
P SH
Nov 30, 2018 10:22AM ET
DATA is opn in 1Q 2019?
0
0
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review